How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Zebrafish Disease Models Market
- By Disease Model Type: Cancer Models, Neurological Disorder Models, Cardiovascular Disease Models, Metabolic Disorder Models, Infectious Disease Models
- By Application: Drug Discovery and Development, Toxicology Testing, Genetic Research, Pathophysiology Studies, Behavioral Studies
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Government and Regulatory Agencies
- By Model Generation Technique: CRISPR/Cas9 Gene Editing, Morpholino Antisense Oligonucleotides, Transgenic Zebrafish Models, Chemical Induction Models, Spontaneous Mutation Models
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Cancer Models leads By Disease Model Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 279 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.168 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.176 →
Full report · locked preview
Everything inside the Zebrafish Disease Models Market report
A complete, evidence-based study - 11 chapters and 117 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Disease Model Type 5
Application 5
End User 4
Model Generation Technique 5
Companies profiled
Charles River Laboratories
Envigo (a part of Inotiv)
Genetic Models Inc.
Zebrafish International Resource Center (ZIRC)
Aquaneering Inc.
Pentair Aquatic Eco-Systems
ZeClinics
DanioLabs
InVivo Biosystems
Vibrent Health
Axol Bioscience
Biocytogen
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Charles River Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Envigo (a part of Inotiv)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Genetic Models Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Zebrafish International Resource Center (ZIRC)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Aquaneering Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Pentair Aquatic Eco-Systems
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →ZeClinics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →DanioLabs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →InVivo Biosystems
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Vibrent Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Axol Bioscience
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Biocytogen
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cyagen Biosciences
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Model Animal Research Center of NIBS (Chinese Academy of Sciences)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Horizon Discovery Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$6,817M by 2033 · 8.0% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Cancer Models61.0
- Neurological Disorder Models11.0
- Cardiovascular Disease Models11.3
- Metabolic Disorder Models8.9
- Infectious Disease Models7.9
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,213M → $2,050M · 6.8%
Europe$845.2M → $1,754M · 9.6%
Asia Pacific$771.7M → $1,525M · 8.9%
Latin America$477.7M → $847.2M · 7.4%
Middle East and Africa$367.5M → $762.7M · 9.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.992026
8.002027
8.002028
8.032029
8.022030
8.032031
8.062032
8.072033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Charles River Laboratories19.2
- Envigo (a part of Inotiv)19.6
- Genetic Models Inc.6.9
- Zebrafish International Resource Center (ZIRC)8.2
- Aquaneering Inc.10.6
- Pentair Aquatic Eco-Systems7.6
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Disease Model Type33.2%
Application25.3%
End User24.3%
Model Generation Technique17.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.5
- Europe25.3
- Asia Pacific22.0
- Latin America12.2
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Charles River Laboratories | 79 | 95 | 87 | 88 | 95 | 88 | 89 |
| Envigo (a part of Inotiv) | 86 | 91 | 87 | 89 | 75 | 76 | 84 |
| Genetic Models Inc. | 78 | 73 | 63 | 87 | 79 | 87 | 78 |
| Zebrafish International Resource Center (ZIRC) | 79 | 63 | 59 | 63 | 71 | 62 | 66 |
| Aquaneering Inc. | 56 | 72 | 54 | 65 | 69 | 60 | 63 |
| Pentair Aquatic Eco-Systems | 66 | 50 | 62 | 60 | 53 | 70 | 60 |
| ZeClinics | 56 | 65 | 45 | 56 | 53 | 44 | 53 |
| DanioLabs | 39 | 39 | 55 | 36 | 58 | 58 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Charles River Laboratories
- Envigo (a part of Inotiv)
- Genetic Models Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Charles River Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Envigo (a part of Inotiv) | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Genetic Models Inc. | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Zebrafish International Resource Center (ZIRC) | ✓ | − | − | ◐ | − | ◐ |
| Aquaneering Inc. | ◐ | ◐ | − | ✓ | ◐ | ◐ |
| Pentair Aquatic Eco-Systems | ◐ | − | − | ◐ | − | ◐ |
| ZeClinics | − | − | − | ◐ | ◐ | − |
| DanioLabs | − | − | ◐ | − | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Charles River Laboratories89
2Envigo (a part of Inotiv)84
3Genetic Models Inc.78
4Zebrafish International Resource Center (ZIRC)66
5Aquaneering Inc.63
6Pentair Aquatic Eco-Systems60
7ZeClinics53
8DanioLabs48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Charles River LaboratoriesEnvigo (a part of Inotiv)Genetic Models Inc.
Contender3
Focused players with pockets of strength.
Zebrafish International Resource Center (ZIRC)Aquaneering Inc.Pentair Aquatic Eco-Systems
Niche2
Specialists in a single segment or region.
ZeClinicsDanioLabs
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Disease Model Type in North America, then scale across Zebrafish Disease Models Market — a $584M beachhead inside a $9.73B market.
Beachhead (SOM)$584Mobtainable near-term
Serviceable (SAM)$3.57Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Cancer Models
Best fit — highest urgency & budget in Disease Model Type.
Economic buyer77 fit
Neurological Disorder Models
Strong fit — clear ROI and a fast path to value.
End user66 fit
Cardiovascular Disease Models
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Disease Model Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales47%
Partner / channel29%
Digital / self-serve17%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Disease Model Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Zebrafish Disease Models Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified39%
Sales qualified23%
Evaluation13%
Closed-won8%
$13.9KCAC
$68KLTV
4.9:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Zebrafish Disease Models Market is a resilient opportunity — $6.60B by 2033, compounding at 5.8%.
TAM · 2025$4.20Btoday
TAM · 2033$6.60Bforecast
CAGR5.8%2027–2033
Cumulative$47.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.60BTotal addressable market
SAM$2.64BServiceable available market
SOM$483MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.8% CAGR
Demand compounds through 2033, outpacing GDP across Disease Model Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Disease Model Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.60BLarge & growingTAM by 2033 at 5.8% CAGR
$2.64BServiceable nowreachable with today’s model
$483MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.15BBear3.8% CAGR
$6.60BBase5.8% CAGR
$8.45BBull7.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Zebrafish Disease Models Market — a $3.11B market by 2033. Plan: grow share from 11.8% to 18.6%.
Market size · 2033$3.11Btotal addressable
Market CAGR6.7%2027–2033
Target share18.6%from 11.8% today
Revenue ambition$578Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 11.8% | 18.6% | On track |
| Revenue | $360M | $578M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 29.6% | 39.3% | Behind |
| Customer retention | 90.0% | 94.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Disease Model Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Disease Model Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $84M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Disease Model Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Zebrafish Disease Models Market conversation — a $3.00B market you can size, segment and defend in minutes.
Market size · 2033$3.00Btotal opportunity
Growth3.8%CAGR to 2033
Addressable buyers1,345+accounts in scope
Typical ROI4.7×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Disease Model Type
Goal Grow share in Disease Model Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.7×return on cost, year one
< 3 mopayback period
$62K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Charles River LaboratoriesEnvigo (a part of Inotiv)Genetic Models Inc.Zebrafish International Resource Center (ZIRC)Aquaneering Inc.Pentair Aquatic Eco-SystemsZeClinicsDanioLabs+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Zebrafish Disease Models Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Zebrafish Disease Models Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Zebrafish as a Model Organism Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportZearalenone Immunoaffinity Columns (IAC) Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportZearalenone Antibody Market
Market size, share, segmentation and regional forecast.
$6.1B market · 2025 base year
View reportZ-D-Glu-ome Reagent Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportZatebradine Hydrochloride Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportZ-Arg(NO2)-OH Reagent Market
Market size, share, segmentation and regional forecast.
$660M market · 2025 base year
View reportZaoren Anshen Granules Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportZanubrutinib Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportZanamivir Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportZaltoprofen Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportZaleplon Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportZaleplon API Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.